Showing 2601-2610 of 3315 results for "".
- Alcon: Cataract Surgery with AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependencehttps://modernod.com/news/alcon-cataract-surgery-with-acrysof-iq-vivity-iols-demonstrates-sustained-high-patient-satisfaction-and-reduced-spectacle-dependence/2481819/Alcon revealed final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post-cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL). Data from
- Eye Care Charity Orbis Announces New Partnership with Heidelberg Engineeringhttps://modernod.com/news/eye-care-charity-orbis-announces-new-partnership-with-heidelberg-engineering/2481817/Orbis announced a new partnership with Heidelberg Engineering in which Heidelburg will fund crucial teaching opportunities and research—focusing on training eye care professionals around the world via Cybersight (Orbis’s telemedicine and e-learning p
- CooperVision to Spotlight Myopia Control and Management Advocacy at ESCRShttps://modernod.com/news/coopervision-to-spotlight-myopia-control-and-management-advocacy-at-escrs/2481809/CooperVision will spotlight advancing myopia control and management as standard of care across all ocular health sectors at the 2023 European Society of Cataract and Refractive Surgeons (ESCRS) conference in Vienna. On September 7, a thought leadership panel will be held
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Sydnexis Appoints Nick Ruth Chief as Commercial Officerhttps://modernod.com/news/sydnexis-appoints-nick-ruth-chief-as-commercial-officer/2481799/Sydnexis has announced the appointment of industry veteran Nick Ruth, MBA, as its Chief Commercial Officer (COO). Mr. Ruth will lead Sydnexis’ commercial strategy and transition from a clinical based organization to both a clinical and commercial based organization. With
- Short-Term Use of Immunosuppressants for Ocular Inflammatory Diseases Not Linked to Cancer Riskhttps://modernod.com/news/short-term-use-of-immunosuppressants-for-ocular-inflammatory-diseases-not-linked-to-cancer-risk/2481793/Relatively short-term use of immunosuppressant medications to control noninfectious ocular inflammatory diseases was not associated with an increased risk of later developing cancer, according to new research led by scientists at the University of Pittsburgh and Mass Eye and Ear, a member of
- Zeiss Surpasses 8 Million Eyes Treated with SMILE Worldwidehttps://modernod.com/news/zeiss-surpasses-8-million-eyes-treated-with-smile-worldwide/2481789/Zeiss announced that more than 8 million eyes have been treated with Small Incision Lenticule Extraction (SMILE) globally to date. The FDA approved the VisuMax Femtosecond Laser for the SMILE procedure in 2016. “Zeiss SMILE is a game-changer for lase
- Neurophth Announces First Patient Dosed in Phase 1/2 Clinical Trial of Second Gene Therapyhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-12-clinical-trial-of-second-gene-therapy/2481786/Neurophth Therapeutics announced that the first patient has been dosed in the international multi-region, multicenter phase 1/2 clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON). Neurophth is conducting a phase 1/2, mu
- AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107https://modernod.com/news/asclepix-therapeutics-raises-10-million-to-advance-phase-12a-clinical-study-of-axt107/2481749/AsclepiX Therapeutics announced that it has secured a $10 million Series A-3 financing to advance clinical development of its lead candidate, AXT107 (gersizangitide), in patients with wet AMD. “With the completion of this round, we are excited to embark into the next phase of
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is